ATE370934T1 - Substituierte dihydrophenanthridin-sulfonamide - Google Patents
Substituierte dihydrophenanthridin-sulfonamideInfo
- Publication number
- ATE370934T1 ATE370934T1 AT03796577T AT03796577T ATE370934T1 AT E370934 T1 ATE370934 T1 AT E370934T1 AT 03796577 T AT03796577 T AT 03796577T AT 03796577 T AT03796577 T AT 03796577T AT E370934 T1 ATE370934 T1 AT E370934T1
- Authority
- AT
- Austria
- Prior art keywords
- dihydrophenanthridine
- sulfonamides
- substituted
- arthritis
- diseases
- Prior art date
Links
- -1 DIHYDROPHENANTHRIDINE SULFONAMIDES Chemical class 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 206010003246 arthritis Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43094902P | 2002-12-04 | 2002-12-04 | |
| US10/718,461 US6894061B2 (en) | 2002-12-04 | 2003-11-20 | Substituted dihydrophenanthridinesulfonamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE370934T1 true ATE370934T1 (de) | 2007-09-15 |
Family
ID=32474616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03796577T ATE370934T1 (de) | 2002-12-04 | 2003-12-02 | Substituierte dihydrophenanthridin-sulfonamide |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6894061B2 (de) |
| EP (1) | EP1567502B1 (de) |
| JP (1) | JP4465280B2 (de) |
| KR (1) | KR20050085321A (de) |
| AT (1) | ATE370934T1 (de) |
| AU (1) | AU2003298819A1 (de) |
| BR (1) | BR0316196A (de) |
| CA (1) | CA2508329A1 (de) |
| CR (1) | CR7854A (de) |
| DE (1) | DE60315874T2 (de) |
| DK (1) | DK1567502T3 (de) |
| EC (1) | ECSP055832A (de) |
| ES (1) | ES2291739T3 (de) |
| MX (1) | MXPA05006003A (de) |
| NO (1) | NO20053204L (de) |
| NZ (1) | NZ540440A (de) |
| RU (1) | RU2005118070A (de) |
| TW (1) | TW200510322A (de) |
| WO (1) | WO2004050631A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050119276A1 (en) * | 2003-09-24 | 2005-06-02 | Wyeth | Methods of treating inflammatory bowel disease using NF-kB inhibitors |
| US20050113405A1 (en) * | 2003-09-24 | 2005-05-26 | Wyeth | Methods of treating rheumatoid arthritis using NF-kB inhibitors |
| EP1652841A1 (de) * | 2004-04-30 | 2006-05-03 | Switch Biotech Aktiengesellschaft | Neue Phenanthridinderivate als Inhibitoren der Hyperproliferation von T Zellen und/oder Keratinocyten |
| CN1968932A (zh) * | 2004-06-18 | 2007-05-23 | 惠氏公司 | 制备6－烷基－5－芳基磺酰基－二氢菲啶的方法 |
| US7304073B2 (en) * | 2004-08-20 | 2007-12-04 | Wyeth | Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors |
| CN101052623A (zh) * | 2004-09-02 | 2007-10-10 | 惠氏公司 | 作为细胞因子调节剂的菲啶羰基酚类 |
| US7555415B2 (en) | 2005-01-19 | 2009-06-30 | Wyeth | Methods for the design of estrogen receptor ligands |
| HU230518B1 (hu) * | 2005-12-20 | 2016-10-28 | Richter Gedeon Nyrt. | Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények |
| TW200829578A (en) | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
| JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
| TW200848021A (en) | 2007-03-06 | 2008-12-16 | Wyeth Corp | Sulfonylated heterocycles useful for modulation of the progesterone receptor |
| ES2569660T3 (es) | 2007-06-08 | 2016-05-12 | Mannkind Corporation | Inhibidores de la IRE-1alfa |
| UY31832A (es) | 2008-05-20 | 2010-01-05 | Astrazeneca Ab | Derivados de indazol sustituidos con fenilo y benzodioxinilo |
| WO2015171558A2 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE |
| EP3140291A4 (de) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydrochinolinsulfonamid und verwandte verbindungen zur verwendung als rory-agonisten und behandlung von krankheiten |
| WO2016179343A1 (en) * | 2015-05-05 | 2016-11-10 | Lycera Corporation | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE |
| CN107980042B (zh) | 2015-06-11 | 2021-10-08 | 莱斯拉公司 | 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物 |
| WO2020117894A1 (en) * | 2018-12-05 | 2020-06-11 | The Board Of Trustees Of The University Of Illinois | Isocarbostyril alkaloids and functionalization thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1135947A (en) | 1965-04-20 | 1968-12-11 | Aspro Nicholas Ltd | Novel biologically active derivatives of phenanthridone |
| US5153185A (en) | 1991-04-16 | 1992-10-06 | Merck & Co., Inc. | 2-phenanthridonyl carbapenems |
| EP0509756A1 (de) | 1991-04-16 | 1992-10-21 | Merck & Co. Inc. | 2-Phenanthridonyl-carbapeneme mit kationisierenden Substituenten |
| CA2066132A1 (en) | 1991-04-16 | 1992-10-17 | Thomas A. Rano | 2-phenanthridonyl carbapenems |
| US5726186A (en) | 1995-09-08 | 1998-03-10 | Eli Lilly And Company | Pentacyclic compounds, intermediates, processes, compositions, and methods |
| PT1000035E (pt) | 1997-07-25 | 2003-04-30 | Altana Pharma Ag | 6-fenilfenantridinas substituidas |
| EE05105B1 (et) | 1999-01-15 | 2008-12-15 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Fenlfenantridiinid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim |
| ATE356810T1 (de) | 1999-01-15 | 2007-04-15 | Altana Pharma Ag | Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung |
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| WO2002005616A1 (en) | 2000-07-14 | 2002-01-24 | Altana Pharma Ag | Novel 6-phenylphenanthridines |
| US6777446B2 (en) | 2000-09-05 | 2004-08-17 | Tularik, Inc. | FXR modulators |
-
2003
- 2003-11-20 US US10/718,461 patent/US6894061B2/en not_active Expired - Fee Related
- 2003-12-02 EP EP03796577A patent/EP1567502B1/de not_active Expired - Lifetime
- 2003-12-02 BR BR0316196-0A patent/BR0316196A/pt not_active IP Right Cessation
- 2003-12-02 JP JP2004557494A patent/JP4465280B2/ja not_active Expired - Fee Related
- 2003-12-02 RU RU2005118070/04A patent/RU2005118070A/ru not_active Application Discontinuation
- 2003-12-02 CA CA002508329A patent/CA2508329A1/en not_active Abandoned
- 2003-12-02 NZ NZ540440A patent/NZ540440A/en unknown
- 2003-12-02 AT AT03796577T patent/ATE370934T1/de not_active IP Right Cessation
- 2003-12-02 MX MXPA05006003A patent/MXPA05006003A/es active IP Right Grant
- 2003-12-02 KR KR1020057010047A patent/KR20050085321A/ko not_active Ceased
- 2003-12-02 DE DE60315874T patent/DE60315874T2/de not_active Expired - Lifetime
- 2003-12-02 WO PCT/US2003/038290 patent/WO2004050631A1/en not_active Ceased
- 2003-12-02 AU AU2003298819A patent/AU2003298819A1/en not_active Withdrawn
- 2003-12-02 ES ES03796577T patent/ES2291739T3/es not_active Expired - Lifetime
- 2003-12-02 DK DK03796577T patent/DK1567502T3/da active
- 2003-12-04 TW TW092134185A patent/TW200510322A/zh unknown
-
2005
- 2005-06-02 EC EC2005005832A patent/ECSP055832A/es unknown
- 2005-06-02 CR CR7854A patent/CR7854A/es not_active Application Discontinuation
- 2005-06-30 NO NO20053204A patent/NO20053204L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4465280B2 (ja) | 2010-05-19 |
| DK1567502T3 (da) | 2007-10-29 |
| WO2004050631A1 (en) | 2004-06-17 |
| ECSP055832A (es) | 2005-08-11 |
| US20040167155A1 (en) | 2004-08-26 |
| BR0316196A (pt) | 2005-09-27 |
| CR7854A (es) | 2006-04-28 |
| DE60315874D1 (de) | 2007-10-04 |
| RU2005118070A (ru) | 2006-01-27 |
| JP2006510631A (ja) | 2006-03-30 |
| KR20050085321A (ko) | 2005-08-29 |
| DE60315874T2 (de) | 2008-05-15 |
| NO20053204L (no) | 2005-09-05 |
| CA2508329A1 (en) | 2004-06-17 |
| AU2003298819A1 (en) | 2004-06-23 |
| ES2291739T3 (es) | 2008-03-01 |
| TW200510322A (en) | 2005-03-16 |
| EP1567502B1 (de) | 2007-08-22 |
| NO20053204D0 (no) | 2005-06-30 |
| US6894061B2 (en) | 2005-05-17 |
| EP1567502A1 (de) | 2005-08-31 |
| NZ540440A (en) | 2006-11-30 |
| MXPA05006003A (es) | 2005-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60315874D1 (de) | Substituierte dihydrophenanthridin-sulfonamide | |
| MXPA05011581A (es) | Derivados de acido 3-(1-naftil)-2-cianopropanoico como ligandos receptores de estrogenos. | |
| EA200500017A1 (ru) | Новые соединения | |
| CY1111225T1 (el) | Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c | |
| TR200201187T2 (tr) | Ters transkriptazın inhibitörleri olarak benzofenonlar | |
| NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
| MX2010003612A (es) | Derivados de oxadiazol. | |
| CY1111363T1 (el) | Τρικυκλικος ανταγωνιστης υποδοχεων θρομβινης | |
| EA201070423A1 (ru) | Диарильные соединения оксадиазолов | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| EA200501274A1 (ru) | Пиразолы и способы их получения и применения | |
| BR0104424A (pt) | Composições de pirazol úteis como inibidores de erk | |
| NO20060825L (no) | Imaging Agents | |
| ATE240328T1 (de) | Substituierte azaoxindolederivate | |
| DE60226154D1 (de) | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung | |
| ATE290382T1 (de) | Heterozyklische kalium-kanal inhibitoren | |
| UY26851A1 (es) | Derivados de la 4-fenilpiridina | |
| NO20070089L (no) | DPP-IV inhibitorer | |
| EA200300392A1 (ru) | Производные пиперазина с мостиковой связью | |
| BRPI0408117A (pt) | compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos | |
| EA200400438A1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной гипертонии | |
| AU7122501A (en) | Aryl sulfonamides as serotonin antagonist for the treatment of obesity | |
| BRPI0415355A (pt) | triarilimidazóis | |
| NO20053562L (no) | Nye aminobenzofenonforbindelser | |
| DE60329323D1 (de) | Substituierte heterozyklische verbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |